| **Contacts:** | **Progenics                Pharmaceuticals, Inc.:** Investor                Contact:Richard                W. Krawiec, Ph.D.Vice                PresidentCorporate                Affairs(914)                789-2800rkrawiec@progenics.com Media                Contact:Aline                SchimmelWeissComm                Partners(212)                301-7218  | **Wyeth:** Media                Contact:Sal                FotiWyeth                Pharmaceuticals(484)                865-3490 Investor                Contact:Justin                VictoriaWyeth(973)                660-5340 |
|---------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|

**WYETH      AND PROGENICS INITIATE NEW CLINICAL STUDIES TO INVESTIGATE ADDITIONAL PATIENT      POPULATIONS FOR METHYLNALTREXONE**

|   |   | ***Companies                begin two phase 3 trials and one phase 2 trial*** |
|--------|--------|-------------------------------------------------------------------------------|

**Collegeville,      Pa., and Tarrytown, N.Y., Sept. 11, 2007**

----

*www.clinicaltrials.gov*

**About      Opioid-Induced Constipation**

**About      Post-Operative Ileus**

----

**About      Methylnaltrexone and the Methylnaltrexone Clinical Program**

**About      the Companies**

**Wyeth      Pharmaceuticals**

**WYETH      DISCLOSURE NOTICE: **
*The statements in this press release that are      not historical facts are forward-looking statements based on current      expectations of future events and are subject to risks and uncertainties that      could cause actual results to differ materially from those expressed or implied      by such statements. These risks and uncertainties include the inherent      uncertainty of the timing and success of, and expense associated with, research,      development, regulatory approval and commercialization of our products,      including with respect to our pipeline products; government cost-containment      initiatives; restrictions on third-party payments for our products; substantial      competition in our industry, including from branded and generic products; data      generated on our products; the importance of strong performance from our      principal products and our anticipated new product introductions; the highly      regulated nature of our business; product liability, intellectual property      and      other litigation risks and environmental liabilities; uncertainty regarding      our      intellectual property rights and those of others; difficulties associated with,      and regulatory compliance with respect to, manufacturing of our products; risks      associated with our strategic relationships; economic conditions including      interest and currency exchange rate fluctuations; changes in generally accepted      accounting principles; trade buying patterns; the impact of legislation and      regulatory compliance; risks and uncertainties associated with global operations      and sales; and*
* *

*other      risks and uncertainties, including those detailed from time to time in our      periodic reports filed with the Securities and Exchange Commission, including      our current reports on Form 8-K, quarterly reports on Form 10-Q and annual      report on Form 10-K, particularly the discussion under the caption “Item 1A,      RISK FACTORS.” The forward-looking statements in this press release are      qualified by these risk factors. We assume no obligation to publicly update      any      forward-looking statements, whether as a result of new information, future      developments or otherwise.*

----

**Progenics      Pharmaceuticals,      Inc**
*in vivo*

**PROGENICS      DISCLOSURE      NOTICE:**
* The information contained in this document is current as of      September 11, 2007. This press release contains forward-looking statements.      Any      statements contained herein that are not statements of historical fact may      be      forward-looking statements. When the Company uses the words “anticipates,”“plans,” “expects” and similar expressions, it is identifying forward-looking      statements. Such forward-looking statements involve risks and uncertainties      which may cause the Company’s actual results, performance or achievements to be      materially different from those expressed or implied by forward-looking      statements. Such factors include, among others, the uncertainties associated      with product development, the risk that clinical trials will not commence or      proceed as planned, the risks and uncertainties associated with dependence      upon      the actions of our corporate, academic and other collaborators and of government      regulatory agencies, the risk that our licenses to intellectual property may      be      terminated because of our failure to have satisfied performance milestones,      the      risk that products that appear promising in early clinical trials do not      demonstrate efficacy in larger-scale clinical trials, the risk that we may      not      be able to manufacture commercial quantities of our products, the uncertainty      of      future profitability and other factors set forth more fully in the Company’s      Annual Report on Form 10-K for the fiscal year ended December 31, 2006, and      other reports filed with the Securities and Exchange Commission, to which      investors are referred for further information. In particular, the Company      cannot assure you that any of its programs will result in a commercial      product.*

*Progenics      does not have a policy of updating or revising forward-looking statements and      assumes no obligation to update any forward-looking statements contained in      this      document as a result of new information or future events or developments. Thus,      it should not be assumed that the Company’s silence over time means that actual      events are bearing out as expressed or implied in such forward-looking      statements.*